Bruker Corporation Reports Slight Revenue Decline in Q2 2025, Operating Income Drops 75%

Bruker Corporation reported its financial results for the second quarter of 2025, revealing a slight decline in total revenue to $797.4 million, down 0.4% from $800.7 million in the same period last year. The company's product revenue decreased by 3.0% to $634.7 million, while service and other revenue increased by 11.2% to $162.7 million. For the first half of 2025, total revenue rose to $1.598 billion, a 5.0% increase compared to $1.522 billion in the first half of 2024. The gross profit margin also saw a decline, dropping to 44.9% from 48.0% year-over-year, attributed to increased costs of goods sold and a shift in sales mix.

In terms of profitability, Bruker reported an operating income of $11.9 million for the second quarter, a significant decrease of 75.3% from $48.1 million in the prior year. The operating income margin fell to 1.5% from 6.0%. The company’s net income attributable to Bruker Corporation remained stable at $7.6 million, while consolidated net income decreased to $4.2 million from $7.6 million a year earlier. The decline in operating income was primarily driven by increased operating expenses, which rose to $346.0 million, up 2.8% from $336.5 million in the previous year.

Bruker has been active in strategic acquisitions, completing several in 2024 and 2025 that have contributed to its revenue growth. Notably, the acquisition of ELITechGroup and NanoString Technologies has expanded its product offerings in molecular diagnostics and life sciences. The company reported that revenues from these acquisitions contributed positively to its overall performance, although organic revenue growth faced challenges due to slower demand in the biopharma and industrial markets.

Operationally, Bruker’s total assets increased to $6.34 billion as of June 30, 2025, compared to $5.81 billion at the end of 2024. The company’s cash and cash equivalents decreased to $92.0 million from $183.4 million, reflecting cash used in operations and investments. The company also reported a total debt of $2.44 billion, up from $2.09 billion, indicating increased leverage as it continues to invest in growth opportunities. Looking ahead, Bruker anticipates further restructuring initiatives aimed at reducing costs by $100 million to $120 million in 2026, as it navigates ongoing market challenges and seeks to enhance operational efficiency.